ClinicalTrials.gg
CompletedNCT04186403Updated Oct 3, 2024Results posted

Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

A Phase 2/3 interventional study of Brexpiprazole in Borderline Personality Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
201
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.

Enrollment
11th of 71
201 · median 56
Started
2020
with 4 others
Phase 2/3
Only one
of the 81
Registered
49th of 81
by date

Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 11th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2020, is the only one in phase 2/3, and was the 49th registered.

Borderline Personality Disorder

278 studies on the registry are indexed under Borderline Personality Disorder; 69 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Borderline Personality Disorder studies recruiting now, 18 (38%) set no upper age limit and 29 (60%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Borderline Personality Disorder with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.

03

Conditions studied

  • Borderline Personality Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants, who completed the last treatment visit of the previous double-blind brexpiprazole BPD trial and who, in the opinion of the investigator, could potentially benefit from administration of brexpiprazole for the treatment of BPD.
  • Male or female outpatients, ages 18 to 65 years, inclusive, at the time of of the previous double-blind brexpiprazole BPD trial.

Exclusion criteria

Exclusion Criteria:

  • Sexually active males or females of (FOCBP) who do not agree to practice 2 different methods of or remain abstinent during the trial and for 30 days after the last dose of IMP. Male participants must also agree not to donate sperm from trial screening/baseline through 30 days after the last dose of medicinal product (IMP).
  • Women who are breastfeeding and/or who have a positive pregnancy test result prior to receiving IMP.
  • Participants who participated in a clinical trial within 90 days prior to screening/baseline (with the exception of a previous brexpiprazole double-blind BPD trial) or who participated in more than 2 clinical trials within a year prior to screening/baseline.
  • Participants who develop a medically significant abnormality.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Prior Brexpiprazole 2-3 Milligrams Per Day

    Participants who received blinded brexpiprazole 2 to 3 milligrams per day (mg/day) in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.

    Drug: Brexpiprazole

  • Experimental
    Prior Placebo

    Participants who received blinded brexpiprazole matching placebo in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.

    Drug: Brexpiprazole

Interventions

  • Administered as tablets.

    Also known as: Rexulti, OPC-34712

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and as Per Severity

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with an onset date on or after the start of open-label treatment. The severity of AEs was graded on a 3-point scale: 1=Mild (Discomfort noticed, but no disruption to daily activity), 2=Moderate (Discomfort sufficient to reduce or affect normal daily activity), and 3=Severe (Inability to work or perform normal daily activity).

    Time frame: Signing of ICF up to 30 days post last dose of study drug (up to approximately 16 weeks)

Secondary outcomes

  1. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

    Potentially clinically significant ECG abnormalities included rate: Bradycardia (vent \<=50 beats per minute \[bpm\] and decrease \>=15 bpm); Rhythm: Sinus bradycardia (\<=50 bpm and decrease \>=15 bpm), absence during baseline and presence of ventricular premature beat post baseline; ST/T morphology: Absence at baseline and presence of symmetrical T-wave inversion post baseline.

    Time frame: Screening up to Week 12

  2. Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities

    Potentially clinically significant vital sign abnormalities included: Heart rate standing in bpm (\<50 bpm and decrease \>=15 bpm, \>120 bpm and increase \>=15 bpm); Weight in kilograms (kgs) (decrease \>=7%, increase \>=7%).

    Time frame: Screening up to Week 12

  3. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities

    Potentially clinically significant laboratory abnormalities included serum chemistry: Prolactin \>upper limit of normal (ULN) (nanograms per millilitre \[ng/ml\] in males and females), fasting glucose ≥100 (milligrams per decilitre \[mg/dl\]), fasting high-density lipoprotein (HDL) cholesterol \<40 (men)/ \<50 (women) (mg/dl), fasting low-density lipoprotein (LDL) cholesterol ≥160 (mg/dl), fasting cholesterol ≥240 (mg/dl), fasting triglycerides ≥150 (mg/dl); Creatine phosphokinase (CPK)/renal: Creatine kinase \>3xULN (units per litre \[U/l\]), creatinine ≥2.0 (mg/dl), urea nitrogen ≥30 (mg/dl).

    Time frame: Screening up to Week 12

  4. Change From Baseline in Simpson-Angus Scale (SAS) Total Score

    The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.

    Time frame: Baseline and Week 12

  5. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

    The AIMS scale consists of 10 items describing symptoms of dyskinesia: Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) (for item 10, no awareness) to 4 (severe condition) (for item 10, awareness, severe distress). AIMS total score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.

    Time frame: Baseline and Week 12

  6. Change From Baseline in Barnes Akathisia Rating Scale (BARS): Global Clinical Assessment of Akathisia Score

    The BARS consists of 4 items related to akathisia: Objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The fourth item, global clinical evaluation was rated on a 6-point scale, with a score range of 0 (absence of symptoms) to 5 (severe akathisia). Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.

    Time frame: Baseline and Week 12

  7. Number of Participants With Suicidal Ideation and Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior.

    Time frame: Baseline up to Week 12

07

Results

Posted Oct 3, 2024

Participant flow

Participants were enrolled at 55 investigational sites in Spain, Ukraine, and the United States (US) from 13 January 2020 to 22 September 2021.

Participant flow — Overall Study
MilestonePrior Brexpiprazole 2-3 Milligrams Per DayPrior Placebo
Started90111
Safety sample88111
Completed7192
Not completed1919
Withdrew: Adverse event18
Withdrew: Lost to follow-up73
Withdrew: Physician decision10
Withdrew: Withdrawal by subject78
Withdrew: Other: not related to covid-1930

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and as Per Severity

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with an onset date on or after the start of open-label treatment. The severity of AEs was graded on a 3-point scale: 1=Mild (Discomfort noticed, but no disruption to daily activity), 2=Moderate (Discomfort sufficient to reduce or affect normal daily activity), and 3=Severe (Inability to work or perform normal daily activity).

Time frame:
Signing of ICF up to 30 days post last dose of study drug (up to approximately 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and as Per Severity
ParticipantsPrior Brexpiprazole 2-3 mg/DayPrior Placebo
TEAEs3056
Mild TEAEs1437
Moderate TEAEs1930
Severe TEAEs34
SecondaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

Potentially clinically significant ECG abnormalities included rate: Bradycardia (vent \<=50 beats per minute \[bpm\] and decrease \>=15 bpm); Rhythm: Sinus bradycardia (\<=50 bpm and decrease \>=15 bpm), absence during baseline and presence of ventricular premature beat post baseline; ST/T morphology: Absence at baseline and presence of symmetrical T-wave inversion post baseline.

Time frame:
Screening up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsPrior Brexpiprazole 2-3 mg/DayPrior Placebo
Bradycardia01
Sinus Bradycardia01
Ventricular Premature Beat01
Symmetrical T-Wave Inversion01
SecondaryNumber of Participants With Potentially Clinically Significant Vital Sign Abnormalities

Potentially clinically significant vital sign abnormalities included: Heart rate standing in bpm (\<50 bpm and decrease \>=15 bpm, \>120 bpm and increase \>=15 bpm); Weight in kilograms (kgs) (decrease \>=7%, increase \>=7%).

Time frame:
Screening up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities
ParticipantsPrior Brexpiprazole 2-3 mg/DayPrior Placebo
Heart Rate Standing31
Weight Decreased74
Weight Increased926
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities

Potentially clinically significant laboratory abnormalities included serum chemistry: Prolactin \>upper limit of normal (ULN) (nanograms per millilitre \[ng/ml\] in males and females), fasting glucose ≥100 (milligrams per decilitre \[mg/dl\]), fasting high-density lipoprotein (HDL) cholesterol \<40 (men)/ \<50 (women) (mg/dl), fasting low-density lipoprotein (LDL) cholesterol ≥160 (mg/dl), fasting cholesterol ≥240 (mg/dl), fasting triglycerides ≥150 (mg/dl); Creatine phosphokinase (CPK)/renal: Creatine kinase \>3xULN (units per litre \[U/l\]), creatinine ≥2.0 (mg/dl), urea nitrogen ≥30 (mg/dl).

Time frame:
Screening up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
ParticipantsPrior Brexpiprazole 2-3 mg/DayPrior Placebo
Prolactin (ng/ml)-Males10
Glucose, Fasting (mg/dL)1311
HDL Cholesterol, Fasting (mg/dL)2219
LDL Cholesterol, Fasting (mg/dL)23
Cholesterol, Fasting (mg/dL)27
Triglycerides, Fasting (mg/dL)1313
SecondaryChange From Baseline in Simpson-Angus Scale (SAS) Total Score

The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Simpson-Angus Scale (SAS) Total Score
score on a scalePrior Brexpiprazole 2-3 mg/DayPrior Placebo
Baseline0.2 ± 0.90.1 ± 0.6
Change From Baseline at Week 12-0.1 ± 0.70.0 ± 0.6
SecondaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

The AIMS scale consists of 10 items describing symptoms of dyskinesia: Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) (for item 10, no awareness) to 4 (severe condition) (for item 10, awareness, severe distress). AIMS total score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
score on a scalePrior Brexpiprazole 2-3 mg/DayPrior Placebo
Baseline0.0 ± 0.10.1 ± 0.8
Change From Baseline at Week 120.0 ± 0.2-0.1 ± 0.9
SecondaryChange From Baseline in Barnes Akathisia Rating Scale (BARS): Global Clinical Assessment of Akathisia Score

The BARS consists of 4 items related to akathisia: Objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The fourth item, global clinical evaluation was rated on a 6-point scale, with a score range of 0 (absence of symptoms) to 5 (severe akathisia). Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Barnes Akathisia Rating Scale (BARS): Global Clinical Assessment of Akathisia Score
score on a scalePrior Brexpiprazole 2-3 mg/DayPrior Placebo
Baseline0.1 ± 0.30.1 ± 0.3
Change From Baseline at Week 12-0.1 ± 0.3-0.0 ± 0.5
SecondaryNumber of Participants With Suicidal Ideation and Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation and Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsPrior Brexpiprazole 2-3 mg/DayPrior Placebo
Suicidal Ideation2828
Suicidal Behavior02

Adverse events

Collected over Signing of ICF up to 30 days post last dose of study drug (up to approximately 16 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prior Brexpiprazole 2-3 mg/Day0/90 (0%)1/88 (1.1%)8/88 (9.1%)
Prior Placebo0/111 (0%)2/111 (1.8%)31/111 (27.9%)
Most frequent serious events
Most frequent serious events
EventPrior Brexpiprazole 2-3 mg/DayPrior Placebo
Suicidal IdeationPsychiatric disorders1/881/111
ContusionInjury, poisoning and procedural complications0/881/111
Most frequent other events
Most frequent other events
EventPrior Brexpiprazole 2-3 mg/DayPrior Placebo
AkathisiaNervous system disorders1/889/111
FatigueGeneral disorders1/887/111
RestlessnessPsychiatric disorders1/887/111
InsomniaPsychiatric disorders5/886/111
Weight increasedInvestigations0/886/111

Baseline characteristics

Enrolled sample included all participants who signed an informed consent form (ICF) and were enrolled into the trial.

Age, Continuous
Age, Continuous(years)Prior Brexpiprazole 2-3 mg/DayPrior PlaceboTotal
Mean33.6 ± 10.532.0 ± 10.632.7 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Prior Brexpiprazole 2-3 mg/DayPrior PlaceboTotal
Female7192163
Male191938
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Prior Brexpiprazole 2-3 mg/DayPrior PlaceboTotal
Race — White7289161
Race — Black or African American71926
Race — American Indian or Alaska Native202
Race — Asian404
Race — Native Hawaiian or Other Pacific Islander011
Race — Other527
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Prior Brexpiprazole 2-3 mg/DayPrior PlaceboTotal
Ethnicity — Hispanic or Latino151732
Ethnicity — Not Hispanic or Latino7593168
Ethnicity — Other011
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    New York, New York 10012, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Sep 2021, 20 months.

Results were first posted in Oct 2024, 3 years after primary completion. A results delay was requested in Sep 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 4, 2019
StartActual
Jan 13, 2020
Primary completionActual
Sep 22, 2021
CompletionActual
Sep 22, 2021
Results delay requested
Sep 21, 2022
Results first posted
Oct 3, 2024
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04186403
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
Jan 13, 2020
Primary completion
Sep 22, 2021
Completion
Sep 22, 2021
Results posted
Oct 3, 2024
Last update
Oct 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion